TRV 250

Drug Profile

TRV 250

Alternative Names: TRV-250

Latest Information Update: 12 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Trevena
  • Class Antimigraines; Small molecules
  • Mechanism of Action Beta arrestin inhibitors; G protein-coupled receptor modulators; Opioid delta receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Migraine

Most Recent Events

  • 04 May 2017 Phase-I clinical trials in Migraine (In volunteers) in USA (SC; PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top